Arrowhead Pharmaceuticals, Inc.

Total Valuation

Arrowhead Pharmaceuticals, Inc. carries a market capitalization of 8.31B, placing it among publicly traded companies globally. Its enterprise value stands at 10.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Arrowhead Pharmaceuticals, Inc. currently has 141.14M shares outstanding.

Valuation Ratios

Arrowhead Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 33.60. The price-to-sales ratio is 17.16, and the price-to-book ratio stands at 24.71.

Enterprise Valuation

On an enterprise value basis, Arrowhead Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 60.20 and an EV/FCF ratio of 191.08. The EV/Sales ratio of 16.26 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 70.67 provides insight into valuation relative to core operating earnings.

Financial Position

Arrowhead Pharmaceuticals, Inc. maintains a current ratio of 5.90, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 211.07, indicating elevated leverage, while an interest coverage ratio of -2.17 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Arrowhead Pharmaceuticals, Inc. has paid 20.05M in income taxes, reflecting an effective tax rate of 55.47.

Stock Price Statistics

Arrowhead Pharmaceuticals, Inc.'s stock has gained approximately 53.00234% over the past 52 weeks. The 50-day moving average sits at 74.95, while the 200-day moving average is 72.04.

Income Statement

Over the trailing twelve months, Arrowhead Pharmaceuticals, Inc. generated 669.50M in revenue and converted that into -319.95M in net income, yielding earnings per share of -1.91. EBITDA reached -200.63M, while operating income came in at -226.44M.

Balance Sheet

Arrowhead Pharmaceuticals, Inc. holds 1.60B in cash and equivalents against 983.69M in total debt, resulting in a net debt position of 844.39M. Total book value stands at 465.53M, with working capital of 1.39B providing operational flexibility.

Cash Flow

Arrowhead Pharmaceuticals, Inc. produced -59.05M in operating cash flow over the past twelve months. After subtracting -16.06M in capital expenditures, free cash flow totaled -75.11M - equivalent to -0.53 per share.

Margins

Arrowhead Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -33.82 and net profit margin of -47.79 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Arrowhead Pharmaceuticals, Inc.'s most recent stock split took place on November 17, 2011 with a 10:1 split ratio.

Scores

Arrowhead Pharmaceuticals, Inc. posts an Altman Z-Score of 3.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.